title: Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms.
abstract: BACKGROUND
  Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis.
  
  
  METHODS
  We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques.
  
  
  RESULTS
  26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p < 0.001) and 53% of adenomas (p < 0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027).
  
  
  CONCLUSIONS
  Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.
authors.affiliation: Department of Medicine and Pathology, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan 48201, USA. martin.tobi@med.va.gov
authors.forename: M
authors.initials: M
authors.lastname: Tobi
authors.forename: J
authors.initials: J
authors.lastname: Hatfield
authors.forename: V
authors.initials: V
authors.lastname: Adsay
authors.forename: K
authors.initials: K
authors.lastname: Galagan
authors.forename: R
authors.initials: R
authors.lastname: Kozarek
authors.forename: M
authors.initials: M
authors.lastname: Inagaki
authors.forename: S
authors.initials: S
authors.lastname: Kasai
authors.forename: Y
authors.initials: Y
authors.lastname: Tokusashi
authors.forename: T
authors.initials: T
authors.lastname: Obara
authors.forename: R H
authors.initials: RH
authors.lastname: Hruban
authors.forename: J
authors.initials: J
authors.lastname: Lough
authors.forename: A N
authors.initials: AN
authors.lastname: Barkun
authors.forename: M
authors.initials: M
authors.lastname: Jabbari
authors.forename: R
authors.initials: R
authors.lastname: Sheikh
authors.forename: B
authors.initials: B
authors.lastname: Ruebner
authors.forename: M J
authors.initials: MJ
authors.lastname: Lawson
authors.forename: E
authors.initials: E
authors.lastname: Ben-Josef
authors.forename: S
authors.initials: S
authors.lastname: Fligiel
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000378:metabolism* / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D023082:Defensins / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D011379:Prognosis
chemical_list: D000911:Antibodies, Monoclonal; D023082:Defensins